Results 221 to 230 of about 2,705,124 (338)

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers. [PDF]

open access: yesClin Cancer Res
Okusanya OO   +8 more
europepmc   +1 more source

Determination of relevant endpoints to evaluate the in vivo barrier function in cutaneous health

open access: diamond, 2019
Emília Alves   +3 more
openalex   +1 more source

Testing A Personalized Approach to Chronic Low Back Pain: A Randomized Controlled Trial in Older Veterans

open access: yesArthritis Care &Research, Accepted Article.
Objective We aimed to test the efficacy of personalized treatment of older Veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABC) as compared with usual care (UC). Methods Two hundred ninety‐nine Veterans age 65‐89 with CLBP from 3 VA medical centers underwent baseline testing, randomization to ABC or UC and 12 months follow ...
Debra K. Weiner   +9 more
wiley   +1 more source

Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis and Persistent Pain: A Randomized Controlled Trial

open access: yesArthritis Care &Research, EarlyView.
Objective Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti‐inflammatory treatment. Digital health applications (DHAs) provide innovative approaches to address multidimensional aspects of persistent pain through psychological and behavioral strategies. The aim of this study was to assess the impact of a DHA
David Kiefer   +7 more
wiley   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

open access: yesArthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti   +19 more
wiley   +1 more source

Has FDA's Drug Development Tools Qualification Program Improved Drug Development? [PDF]

open access: yesTher Innov Regul Sci
Yang F   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy